Recro Pharma, Inc. (REPH) |
| 2.09 -0.01 (-0.48%) 03-22 00:00 |
| Open: | 2.07 |
| High: | 2.14 |
| Low: | 2.0001 |
| Volume: | 137,536 |
| Market Cap: | 177(M) |
| PE Ratio: | -8.04 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 3.29 |
| 52w Low: | 1.38 |
Recro Pharma, Inc. operates as a contract development and manufacturing organization (CDMO), offering comprehensive services for the development, production, and packaging of diverse therapeutic dosage forms. The company primarily specializes in small molecule therapeutic development, serving both domestic U.S. and international clients. Its extensive capabilities encompass a wide array of formats, including oral solid doses, sterile injectable solutions, oral liquid preparations, tablets, topical formulations, liquid/powder-filled capsules, ophthalmic droppers, liposomal products, and nano/microparticles. Furthermore, Recro Pharma provides specialized services such as aseptic fill/finish, lyophilization (freeze-drying), final packaging, and logistics management. Originally founded as Recro Pharma I, Inc., the company underwent a name change to Recro Pharma, Inc. in August 2008. The organization was established in 2007 and is headquartered in Exton, Pennsylvania.
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Mon, 21 Mar 2022
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation - GlobeNewswire
Fri, 13 Aug 2021
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO - GlobeNewswire
Thu, 21 Nov 2019
Recro Pharma completes split into two companies - The Business Journals
Mon, 13 Jun 2016
Iroko Uses Event Monitoring System To Power Phase 3 Trial Of VIVLODEX - Clinical Leader
Wed, 01 Jul 2015
Recro Pharma Announces $16 Million Financing - GlobeNewswire
Wed, 15 Jul 2026
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |